DDrare: Database of Drug Development for Rare Diseases

168. エーラス・ダンロス症候群
［臨床試験数：7，薬物数：16（DrugBank：8），標的遺伝子数：9，標的パスウェイ数：54］

Searched query = "Ehlers-Danlos syndrome", "EDS", "cEDS", "hEDS", "clEDS", "vEDS", "kEDS", "aEDS", "dEDS", "DDEDS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 0.9% Sodium Chloride Injection; Bupivacaine; Bupivacaine Injection 0.5%; Celiprolol; Chloride; Control; Device: Kera-X; IRBESARTAN; Irbesartan; Lidocaine; Lidocaine Injection 2%; Mecasermin; Mind-body therapy; Riboflavin; Saline; Sodium chloride

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01307527 (ClinicalTrials.gov)	November 2008	1/3/2011	Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI		Brittle Cornea Syndrome;Ehlers-Danlos Syndrome Type 6	Drug: Riboflavin;Device: Kera-X	Hadassah Medical Organization	NULL	Enrolling by invitation	18 Years	N/A	Both	1	N/A	Israel

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01307527
(ClinicalTrials.gov)

November 2008

1/3/2011

Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI

Brittle Cornea Syndrome;Ehlers-Danlos Syndrome Type 6

Drug: Riboflavin;Device: Kera-X

Hadassah Medical Organization

NULL

Enrolling by invitation

18 Years

N/A

Both

N/A

Israel